NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

6/12/24 1:07:32 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NKGN alert in real time by email

Get the next $NKGN alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$NKGN

Date	Price Target	Rating	Analyst

More analyst ratings

$NKGN
Leadership Updates

Live Leadership Updates

View All

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

1/22/26 8:05:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

12/3/25 8:05:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

SANTA ANA, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that Anita Fletcher, M.D. has been appointed as the National Principal Investigator ("PI") for its Phase 2a clinical trial of troculeucel, expanded enhanced autologous NK cell therapy, for the treatment of moderate Alzheimer's disease (NCT06189963). In addition to Dr. Fletcher's appointment as National PI, NKGen is pleased to announce AdventHealth Research Institute, Neuroscience Research in Orl

2/19/25 8:00:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$NKGN
Press Releases

Fastest customizable press release news feed in the world

View All

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders ("AD/PD™ 2026"), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually. The presentations will highlight a new integrated analysis of patient-level data from two previously completed Phase 1 studies evaluating troculeucel in patients with

3/10/26 8:05:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

1/22/26 8:05:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

12/3/25 8:05:00 AM ET

$NKGN

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NKGN

NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NKGN

$NKGN
SEC Filings

SEC Form 10-Q filed by NKGen Biotech Inc.

NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$NKGN
Insider Purchases

Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

$NKGN
Insider Trading

Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

$NKGN
Leadership Updates

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

$NKGN
Large Ownership Changes

SEC Form SC 13G filed by NKGen Biotech Inc.

SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

$NKGN
Financials

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

$NKGN
Press Releases

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $NKGN

NKGen Biotech Presents Novel Manufacturing And Cryopreservation Process For Allogeneic NK Cell Therapy SNK02; CEO Dr. Paul Y. Song Updates On Initial Phase 1 Results For Treating Advanced Refractory Solid Tumors

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $NKGN

$NKGN SEC Filings

SEC Form 10-Q filed by NKGen Biotech Inc.

NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

NKGen Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$NKGN Insider Purchases

Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

$NKGN Insider Trading

Large owner Cfic-2015 Nv Family Investments, Llc bought $2,500,000 worth of shares (19,669,552 units at $0.13), increasing direct ownership by 944% to 21,752,885 units (SEC Form 4)

Chief Executive Officer Song Paul Y. bought $2,650,000 worth of shares (20,849,725 units at $0.13), increasing direct ownership by 12,184% to 21,020,846 units (SEC Form 4)

Large owner Graf Acquisition Partners Iv Llc disposed of 63,634 shares (SEC Form 4)

$NKGN Leadership Updates

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer's Disease with AdventHealth Orlando as First East Coast Site

$NKGN Large Ownership Changes

SEC Form SC 13G filed by NKGen Biotech Inc.

SEC Form SC 13G/A filed by NKGen Biotech Inc. (Amendment)

$NKGN Financials

NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights

$NKGN Press Releases

NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

Recent Analyst Ratings for
$NKGN

Recent Analyst Ratings for
$NKGN

$NKGN
SEC Filings

$NKGN
Insider Purchases

$NKGN
Insider Trading

$NKGN
Leadership Updates

$NKGN
Large Ownership Changes

$NKGN
Financials

$NKGN
Press Releases